NYSE:RMED - Ra Medical Systems Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $31.50
  • Forecasted Upside: 443.10 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.80
▲ +0.05 (0.87%)
1 month | 3 months | 12 months
Get New Ra Medical Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RMED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RMED

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$31.50
▲ +443.10% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Ra Medical Systems in the last 3 months. The average price target is $31.50, with a high forecast of $50.00 and a low forecast of $7.00. The average price target represents a 443.10% upside from the last price of $5.80.
Hold
The current consensus among 3 investment analysts is to hold stock in Ra Medical Systems. This rating has held steady since January 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/12/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/11/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/10/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/6/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2020Piper SandlerLower Price TargetNeutral$12.00 ➝ $7.00High
i
7/31/2020Piper SandlerLower Price TargetNeutral$25.00Medium
i
6/12/2020Maxim GroupReiterated RatingBuy$50.00Medium
i
5/15/2020Maxim GroupReiterated RatingBuy$75.00Medium
i
5/14/2020Piper SandlerLower Price TargetNeutral$37.50 ➝ $25.00Low
i
Rating by Matthew O'Brien at Piper Sandler
3/12/2020Maxim GroupReiterated RatingBuyHigh
i
3/11/2020Cantor FitzgeraldLower Price TargetNeutral$50.00 ➝ $37.50High
i
1/21/2020Piper SandlerReiterated RatingHold$37.50High
i
Rating by Matthew O'Brien at Piper Sandler
12/6/2019Maxim GroupReiterated RatingBuy$75.00Low
i
8/13/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$250.00 ➝ $50.00High
i
Rating by C. Bijou at Cantor Fitzgerald
8/13/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$225.00 ➝ $37.50High
i
5/15/2019Maxim GroupLower Price TargetBuy$300.00Low
i
3/26/2019SunTrust BanksReiterated RatingBuy ➝ Positive$250.00Low
i
3/26/2019Cantor FitzgeraldReiterated RatingBuy$275.00Low
i
Rating by Craig Bijou at Cantor Fitzgerald
3/18/2019Cantor FitzgeraldLower Price TargetOverweight$525.00 ➝ $275.00High
i
Rating by Craig Bijou at Cantor Fitzgerald
3/15/2019Maxim GroupLower Price TargetBuy$375.00High
i
11/14/2018Cantor FitzgeraldSet Price TargetBuy$525.00Low
i
Rating by Craig Bijou at Cantor Fitzgerald
11/2/2018Maxim GroupInitiated CoverageBuy ➝ Buy$575.00Medium
i
10/22/2018Piper Jaffray CompaniesInitiated CoverageOverweight$575.00Low
i
10/22/2018Cantor FitzgeraldInitiated CoverageOverweight$525.00High
i
Rating by C. Bijou at Cantor Fitzgerald
10/22/2018SunTrust BanksInitiated CoverageBuy$400.00High
i
(Data available from 3/5/2016 forward)
Ra Medical Systems logo
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $5.80
$5.18
$6.14

50 Day Range

MA: $7.60
$6.59
$8.97

52 Week Range

Now: $5.80
$4.25
$42.00

Volume

274,339 shs

Average Volume

394,694 shs

Market Capitalization

$16.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Ra Medical Systems?

The following equities research analysts have issued stock ratings on Ra Medical Systems in the last year: Cantor Fitzgerald, Maxim Group, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for RMED.

What is the current price target for Ra Medical Systems?

3 Wall Street analysts have set twelve-month price targets for Ra Medical Systems in the last year. Their average twelve-month price target is $31.50, suggesting a possible upside of 447.8%. Maxim Group has the highest price target set, predicting RMED will reach $50.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $7.00 for Ra Medical Systems in the next year.
View the latest price targets for RMED.

What is the current consensus analyst rating for Ra Medical Systems?

Ra Medical Systems currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RMED, but not buy more shares or sell existing shares.
View the latest ratings for RMED.

What other companies compete with Ra Medical Systems?

How do I contact Ra Medical Systems' investor relations team?

Ra Medical Systems' physical mailing address is 2070 Las Palmas Drive, Carlsbad CA, 92011. The company's listed phone number is 760-804-1648 and its investor relations email address is [email protected] The official website for Ra Medical Systems is www.ramed.com.